UnitedHealth is also dealing with government pressure on drug prices and a vow to “knock out” drug middlemen.
The retail buy-the-dip move paid off. What that crowd of investors is doing now, according to JPMorgan.
JPMorgan said retail investors did well with a buy-the-dip strategy last month, but that crowd of investors is getting weary.
